Adverum biotechnologies doses first patient in third cohort of optic phase 1 clinical trial of advm-022 intravitreal gene therapy for wet amd

Patients in the third cohort of optic will receive a single advm-022 dose of 2 x 10 ^11 vg/eye patients in the third cohort of optic will receive a single advm-022 dose of 2 x 10 ^11 vg/eye

AMD Ratings Summary

AMD Quant Ranking